Liposomal Bupivicaine for Skin Graft Donor Sites in Burn Patients

• Status: Unknown status
• Trial end date: 2019-09-30
• Target enrollment: 0
• Participant gender: All

Summary

Burn injuries are painful to patients and the sources of pain result from many areas including: the injury itself, wound care, and surgery. Inpatients that require surgical skin grafting is often required and the donor site of a skin graft is quite painful for patients. The investigators try to minimize that pain with local anesthetic as well as a combination of pain medications, the donor site pain lasts for days and is what patients often report as being the most painful part of their burn care.

There has been the development of a new form of local anesthesia that can last up to 72 hours when injected into tissue. Based on encouraging results in the literature in areas outside of burns, this study aims to evaluate whether administration of this medication at the time of surgery can help improve pain for burn patients in the postoperative period.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Massachusetts General Hospital

Criteria

Inclusion Criteria:

• Burn size ≤15% TBSA

• Anticipated one trip to operating room for single stage excision and grafting

• Total donor site surface area <500cm2

• Opioid naïve prior to admission for treatment of burn

• Patient able to consent

• 18 years or older

Exclusion Criteria:

Medical Exclusions:

• Cardiac arrhythmias

• Heart block

• Pregnancy

• Breast-feeding mothers who will be unable to stop breastfeeding for 8 days post-injection

• Allergy to bupvicaine

• Bradycardia

• Severe liver disease

• Incapacity to consent themselves

• Unlikely to survive burn Burn related exclusions

• Current substance abuse

• On opioids prior to admission

• Burn larger than 15% TBSA

• Prior autografting for this particular burn